| pubmed-article:7634407 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7634407 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:7634407 | lifeskim:mentions | umls-concept:C2698297 | lld:lifeskim |
| pubmed-article:7634407 | lifeskim:mentions | umls-concept:C0005953 | lld:lifeskim |
| pubmed-article:7634407 | lifeskim:mentions | umls-concept:C1511660 | lld:lifeskim |
| pubmed-article:7634407 | lifeskim:mentions | umls-concept:C0005036 | lld:lifeskim |
| pubmed-article:7634407 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:7634407 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:7634407 | pubmed:dateCreated | 1995-9-14 | lld:pubmed |
| pubmed-article:7634407 | pubmed:abstractText | We used P1-enhanced 32P-postlabeling to investigate DNA adduct formation in the bone marrow of B6C3F1 mice treated intraperitoneally with benzene (BZ). No adducts were detected in the bone marrow of controls or mice treated with various doses of BZ once a day. After twice-daily treatment with BZ, 440 mg/kg, for 1 to 7 days, one major and two minor DNA adducts were detected. The relative adduct levels ranged from 0.06-1.46 x 10(-7). In vitro treatment of bone marrow from B6C3F1 mice with various doses of hydroquinone (HQ) for 24 h also produced three DNA adducts. These adducts were the same as those formed after in vivo treatment of bone marrow with BZ. Co-chromatography experiments indicated that the principal DNA adduct detected in the bone marrow of B6C3F1 mice was the same as that detected in HL-60 cells treated with HQ. This finding suggests that HQ may be the principal metabolite of BZ leading to DNA adduct formation in vivo. DNA adduct 2 corresponds to the DNA adduct formed in HL-60 cells treated with 1,2,4-benzenetriol. DNA adduct 3 remains unidentified. After a 7-day treatment with BZ, 440 mg/kg twice a day, the number of cells per femur decreased from 1.6 x 10(7) to 0.85 x 10(7), indicating myelotoxicity. In contrast, administration of BZ once a day produced only a small decrease in bone marrow cellularity. These studies demonstrate that metabolic activation of BZ leads to the formation of DNA adducts in the bone marrow. Further investigation is required to determine the role of DNA adducts and other forms of DNA damage in the myelotoxic effects of exposure to BZ. | lld:pubmed |
| pubmed-article:7634407 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7634407 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7634407 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7634407 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7634407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7634407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7634407 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7634407 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:7634407 | pubmed:issn | 0143-3334 | lld:pubmed |
| pubmed-article:7634407 | pubmed:author | pubmed-author:BodellW JWJ | lld:pubmed |
| pubmed-article:7634407 | pubmed:author | pubmed-author:PathakD NDN | lld:pubmed |
| pubmed-article:7634407 | pubmed:author | pubmed-author:LévayGG | lld:pubmed |
| pubmed-article:7634407 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7634407 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:7634407 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7634407 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7634407 | pubmed:pagination | 1803-8 | lld:pubmed |
| pubmed-article:7634407 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7634407 | pubmed:meshHeading | pubmed-meshheading:7634407-... | lld:pubmed |
| pubmed-article:7634407 | pubmed:meshHeading | pubmed-meshheading:7634407-... | lld:pubmed |
| pubmed-article:7634407 | pubmed:meshHeading | pubmed-meshheading:7634407-... | lld:pubmed |
| pubmed-article:7634407 | pubmed:meshHeading | pubmed-meshheading:7634407-... | lld:pubmed |
| pubmed-article:7634407 | pubmed:meshHeading | pubmed-meshheading:7634407-... | lld:pubmed |
| pubmed-article:7634407 | pubmed:meshHeading | pubmed-meshheading:7634407-... | lld:pubmed |
| pubmed-article:7634407 | pubmed:meshHeading | pubmed-meshheading:7634407-... | lld:pubmed |
| pubmed-article:7634407 | pubmed:meshHeading | pubmed-meshheading:7634407-... | lld:pubmed |
| pubmed-article:7634407 | pubmed:meshHeading | pubmed-meshheading:7634407-... | lld:pubmed |
| pubmed-article:7634407 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7634407 | pubmed:articleTitle | DNA adduct formation in the bone marrow of B6C3F1 mice treated with benzene. | lld:pubmed |
| pubmed-article:7634407 | pubmed:affiliation | Department of Neurological Surgery, School of Medicine, University of California, San Francisco 94143-0806, USA. | lld:pubmed |
| pubmed-article:7634407 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7634407 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7634407 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7634407 | lld:pubmed |
